Literature DB >> 24148766

α-Synuclein and mitochondrial bioenergetics regulate tetrahydrobiopterin levels in a human dopaminergic model of Parkinson disease.

Brent J Ryan1, Lara L Lourenço-Venda1, Mark J Crabtree2, Ashley B Hale2, Keith M Channon2, Richard Wade-Martins3.   

Abstract

Parkinson disease (PD) is a multifactorial disease resulting in preferential death of the dopaminergic neurons in the substantia nigra. Studies of PD-linked genes and toxin-induced models of PD have implicated mitochondrial dysfunction, oxidative stress, and the misfolding and aggregation of α-synuclein (α-syn) as key factors in disease initiation and progression. Many of these features of PD may be modeled in cells or animal models using the neurotoxin 1-methyl-4-phenylpyridinium (MPP(+)). Reducing oxidative stress and nitric oxide synthase (NOS) activity has been shown to be protective in cell or animal models of MPP(+) toxicity. We have previously demonstrated that siRNA-mediated knockdown of α-syn lowers the activity of both dopamine transporter and NOS activity and protects dopaminergic neuron-like cells from MPP(+) toxicity. Here, we demonstrate that α-syn knockdown and modulators of oxidative stress/NOS activation protect cells from MPP(+)-induced toxicity via postmitochondrial mechanisms rather than by a rescue of the decrease in mitochondrial oxidative phosphorylation caused by MPP(+) exposure. We demonstrate that MPP(+) significantly decreases the synthesis of the antioxidant and obligate cofactor of NOS and TH tetrahydrobiopterin (BH4) through decreased cellular GTP/ATP levels. Furthermore, we demonstrate that RNAi knockdown of α-syn results in a nearly twofold increase in GTP cyclohydrolase I activity and a concomitant increase in basal BH4 levels. Together, these results demonstrate that both mitochondrial activity and α-syn play roles in modulating cellular BH4 levels.
© 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bioenergetics; DAT; Free radicals; GTPCH; MPP(+); Parkinson disease; Tetrahydrobiopterin; α-Synuclein

Mesh:

Substances:

Year:  2013        PMID: 24148766      PMCID: PMC5238936          DOI: 10.1016/j.freeradbiomed.2013.10.008

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  41 in total

1.  VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity.

Authors:  N Takahashi; L L Miner; I Sora; H Ujike; R S Revay; V Kostic; V Jackson-Lewis; S Przedborski; G R Uhl
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

2.  alpha-Synuclein locus triplication causes Parkinson's disease.

Authors:  A B Singleton; M Farrer; J Johnson; A Singleton; S Hague; J Kachergus; M Hulihan; T Peuralinna; A Dutra; R Nussbaum; S Lincoln; A Crawley; M Hanson; D Maraganore; C Adler; M R Cookson; M Muenter; M Baptista; D Miller; J Blancato; J Hardy; K Gwinn-Hardy
Journal:  Science       Date:  2003-10-31       Impact factor: 47.728

3.  Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo.

Authors:  T Dehmer; J Lindenau; S Haid; J Dichgans; J B Schulz
Journal:  J Neurochem       Date:  2000-05       Impact factor: 5.372

4.  Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation.

Authors:  L Narhi; S J Wood; S Steavenson; Y Jiang; G M Wu; D Anafi; S A Kaufman; F Martin; K Sitney; P Denis; J C Louis; J Wypych; A L Biere; M Citron
Journal:  J Biol Chem       Date:  1999-04-02       Impact factor: 5.157

5.  Critical role for tetrahydrobiopterin recycling by dihydrofolate reductase in regulation of endothelial nitric-oxide synthase coupling: relative importance of the de novo biopterin synthesis versus salvage pathways.

Authors:  Mark J Crabtree; Amy L Tatham; Ashley B Hale; Nicholas J Alp; Keith M Channon
Journal:  J Biol Chem       Date:  2009-08-07       Impact factor: 5.157

6.  Arginine conversion to nitroxide by tetrahydrobiopterin-free neuronal nitric-oxide synthase. Implications for mechanism.

Authors:  S Adak; Q Wang; D J Stuehr
Journal:  J Biol Chem       Date:  2000-10-27       Impact factor: 5.157

7.  Chronic Parkinsonism secondary to intravenous injection of meperidine analogues.

Authors:  G C Davis; A C Williams; S P Markey; M H Ebert; E D Caine; C M Reichert; I J Kopin
Journal:  Psychiatry Res       Date:  1979-12       Impact factor: 3.222

8.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.

Authors:  J W Langston; P Ballard; J W Tetrud; I Irwin
Journal:  Science       Date:  1983-02-25       Impact factor: 47.728

9.  Assessment of the direct and indirect effects of MPP+ and dopamine on the human proteasome: implications for Parkinson's disease aetiology.

Authors:  Begoña Caneda-Ferrón; Luigi A De Girolamo; Teresa Costa; Katy E Beck; Robert Layfield; E Ellen Billett
Journal:  J Neurochem       Date:  2007-11-16       Impact factor: 5.372

10.  1-Methyl-4-phenylpyridinium (MPP+)-induced apoptosis and mitochondrial oxidant generation: role of transferrin-receptor-dependent iron and hydrogen peroxide.

Authors:  Shasi V Kalivendi; Srigiridhar Kotamraju; Sonya Cunningham; Tiesong Shang; Cecilia J Hillard; B Kalyanaraman
Journal:  Biochem J       Date:  2003-04-01       Impact factor: 3.857

View more
  18 in total

1.  Mitochondrial respiration is sensitive to cytoarchitectural breakdown.

Authors:  Judith Kandel; Alessia A Angelin; Douglas C Wallace; David M Eckmann
Journal:  Integr Biol (Camb)       Date:  2016-11-07       Impact factor: 2.192

2.  Genetic deletion of the GATA1-regulated protein α-synuclein reduces oxidative stress and nitric oxide synthase levels in mature erythrocytes.

Authors:  Raffaele Renella; Julia S Schlehe; Dennis J Selkoe; David A Williams; Matthew J LaVoie
Journal:  Am J Hematol       Date:  2014-07-21       Impact factor: 10.047

3.  2-Year Natural Decline of Cardiac Sympathetic Innervation in Idiopathic Parkinson Disease Studied with 11C-Hydroxyephedrine PET.

Authors:  Ka Kit Wong; David M Raffel; Nicolaas I Bohnen; Gulcin Altinok; Sid Gilman; Kirk A Frey
Journal:  J Nucl Med       Date:  2016-08-18       Impact factor: 10.057

Review 4.  Neuroinflammation in L-DOPA-induced dyskinesia: beyond the immune function.

Authors:  Augusta Pisanu; Laura Boi; Giovanna Mulas; Saturnino Spiga; Sandro Fenu; Anna R Carta
Journal:  J Neural Transm (Vienna)       Date:  2018-03-14       Impact factor: 3.575

5.  Impairment of Nrf2- and Nitrergic-Mediated Gastrointestinal Motility in an MPTP Mouse Model of Parkinson's Disease.

Authors:  C Sampath; R Kalpana; T Ansah; C Charlton; A Hale; K M Channon; S Srinivasan; P R Gangula
Journal:  Dig Dis Sci       Date:  2019-06-11       Impact factor: 3.199

6.  The E3 ubiquitin ligase seven in absentia homolog 1 may be a potential new therapeutic target for Parkinson's disease.

Authors:  Zeng-Lin Cai; Jing Xu; Shou-Ru Xue; Yuan-Yuan Liu; Yong-Jin Zhang; Xin-Zhi Zhang; Xuan Wang; Fang-Ping Wu; Xiao-Min Li
Journal:  Neural Regen Res       Date:  2015-08       Impact factor: 5.135

7.  Dopaminergic Toxin 1-Methyl-4-Phenylpyridinium, Proteins α-Synuclein and Glia Maturation Factor Activate Mast Cells and Release Inflammatory Mediators.

Authors:  Duraisamy Kempuraj; Ramasamy Thangavel; Evert Yang; Sagar Pattani; Smita Zaheer; Donna A Santillan; Mark K Santillan; Asgar Zaheer
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

8.  Parkinson's disease in GTP cyclohydrolase 1 mutation carriers.

Authors:  Brent J Ryan; Mark J Crabtree; Keith M Channon; Richard Wade-Martins
Journal:  Brain       Date:  2014-11-14       Impact factor: 13.501

9.  Reply: Parkinson's disease in GTP cyclohydrolase 1 mutation carriers.

Authors:  Niccolo E Mencacci; Alan M Pittman; Ioannis U Isaias; John Hardy; Stephan Klebe; Kailash P Bhatia; Nicholas W Wood
Journal:  Brain       Date:  2014-11-14       Impact factor: 13.501

10.  Protein-protein interaction networks identify targets which rescue the MPP+ cellular model of Parkinson's disease.

Authors:  Harriet Keane; Brent J Ryan; Brendan Jackson; Alan Whitmore; Richard Wade-Martins
Journal:  Sci Rep       Date:  2015-11-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.